GVR Report cover Contraceptive Drugs And Devices Market Size, Share & Trends Report

Contraceptive Drugs And Devices Market Size, Share & Trends Analysis Report By Product (Contraceptive Drugs (Pills, Patch, Injectable), Contraceptive Devices), By Region, And Segment Forecasts, 2025 - 2030

  • Report ID: 978-1-68038-032-3
  • Number of Report Pages: 100
  • Format: PDF, Horizon Databook
  • Historical Range: 2018 - 2024
  • Forecast Period: 2025 - 2030 
  • Industry: Healthcare

Market Size & Trends

The global contraceptive drugs and devices market size was estimated at USD 31.18 billion in 2024 and is projected to grow at a CAGR of 6.0% from 2025 to 2030. Several factors are contributing to the growth of the contraceptive market. Increasing awareness and education about reproductive health, a rising demand for family planning methods, improved healthcare infrastructure and access, and a shift in consumer preferences toward more effective and convenient contraceptive options are all key drivers. These factors have led to a global demand for a wide range of contraceptive choices, including oral contraceptives and long-acting reversible contraceptives (LARCs) such as intrauterine devices (IUDs) and implants. 

Contraceptive Drugs And Devices Market Size, by Product, 2020 - 2030 (USD Billion)

Furthermore, health concerns related to teenage pregnancies, increased awareness of modern contraception methods, and a growing preference for oral contraceptives as the primary means of preventing unplanned pregnancies are anticipated to drive market growth during the forecast period. In addition, advancements in product innovation, government initiatives, and a focus on women's empowerment and rights have contributed to this market growth. For instance, in July 2023, Opill, a progestin-only oral contraceptive pill, got approval by the FDA for nonprescription use. 

Implementing programs aimed at reducing unwanted pregnancies and related healthcare costs, along with increasing awareness among users, is expected to drive growth in the industry during the forecast period. According to the 2022 State of World Population Report by the United Nations Population Fund (UNFPA), approximately 121 million pregnancies occur worldwide each year, with nearly half of them being unintended.

Moreover, governments in developing countries are undertaking steps to increase awareness and access to contraceptives. For instance, in October 2023, the Karnataka Health Department in India launched two new contraceptive methods for women under the National Family Planning Programme. The sub-dermal implant and subcutaneous injection were made available at government-run health centers to promote reproductive and sexual health by extending the interval between two births. Such methods are expected to promote the use of contraception in developing countries and contribute to the market's growth.

Market Concentration & Characteristics

The market is experiencing a high degree of innovation, especially with the development of long-acting reversible contraceptives (LARCs) and non-hormonal options. For instance, in June 2023, Agile Therapeutics launched TWIRLA (levonorgestrel and ethinyl estradiol) transdermal system, a new non-daily, non-invasive contraceptive patch, is now available and dispensed through FPA clinics in California.

Merger and acquisition activities in the market are at a moderate level. These activities aim to increase awareness, expand the product portfolio, and achieve various other objectives. For instance,in April 2023, Veru entered into a distribution agreement with Afaxys to distribute the FC2 Female Condom, supporting public health initiatives for millions.

Contraceptive Drugs And Devices Industry Dynamics

The impact of regulations on the market is high, as regulatory bodies, including the FDA, play a crucial role in product approval and safety standards. For instance, in November 2022, Lupin's Drospirenone tablets got FDA approval, highlighting the importance of regulatory compliance for market entry. Stringent regulations ensure that only safe and effective products reach consumers, which influences innovation cycles as companies strive to meet these standards. Regulatory frameworks significantly shape product development strategies within the market.

The level of product expansion in the market is high. Traditional methods such as condoms and oral contraceptives remain popular, and emerging alternatives such as vaginal rings and injectable contraceptives are gaining traction. For instance, in October 2023, Xiromed launched a generic version of Nuvaring, a vaginal ring, EnilloRing. The launch of this product offers an additional contraceptive option to patients in the U.S.

The level of regional expansion in the industry is high due to the growing number of unintended pregnancies, which is experiencing significant growth. For instance, in August 2020, Cupid Limited expanded its market presence with approval from the U.S. FDA for the marketing of male condom variants in the U.S. In regions with rapidly growing populations and increasing awareness of reproductive health, such as parts of Asia, Africa, and Latin America, there is a prominent growth in demand for contraceptives. International organizations and non-profits play a crucial role in expanding access to contraceptives in these countries through education, distribution programs, and policy advocacy.

Product Insights

The contraceptive devices segment dominated the market with a share of 68.6% in 2024 and is expected to witness the fastest growth rate over the forecast period. The segment is sub-divided into intrauterine devices (IUDs), condoms, vaginal rings, subdermal implants, and diaphragms. The growth of the segment is attributed to an increase in the awareness level of STDs and the efficiency of condoms in preventing infections, including HIV. According to the World Health Organization (WHO) data, in 2023, there were a total of 630,000 deaths attributed to HIV, with 13% of these fatalities occurring in children younger than 15 years old.

On the other hand, contraceptive drugs are anticipated to witness significant growth owing to increased awareness regarding unwanted pregnancies and preventive measures such as pills, patches, and injectables. Increased accessibility and growing acceptance of contraceptive drugs among the urban population are driving the market growth of this segment, as the population is giving greater importance to sexual health and family planning. A study published by the National Library of Medicine in January 2023 estimated that around 32.9% of women used contraceptive pills as the preferred method of contraception. This convenience and effectiveness of pills as a non-invasive, easily accessible method of birth control contribute to their high market share.

Regional Insights

North America contraceptive drugs and devices market holds a significant revenue share in 2024. The growth of the market across the region can be attributed to the rising population and the increasing prevalence of STDs and unwanted pregnancies in the region. Urban populations are increasingly turning to contraceptive methods to tackle issues such as abortions, unwanted pregnancies, and STDs. New non-hormonal options such as Ovaprene, a monthly vaginal ring that blocks sperm and releases agents to impede sperm motility, are currently in development. These methods aim to provide effective contraception for users who prefer not to use daily pills or long-acting methods. 

Contraceptive Drugs And Devices Market Share, by Region, 2024 (%)

U.S. Contraceptive Drugs and Devices Market Trends

The contraceptive drugs and devices market in U.S. dominated the North America with the largest revenue share in 2024 due to the increasing use of personalized medicine approaches in contraception, where patients choose methods custom-made to their specific health needs and lifestyle preferences. New product launches further contribute to the growth of the market in the country. For instance, in July 2024, Femlyv is the first FDA-approved dissolvable birth control pill, designed for individuals who have difficulty swallowing tablets. It contains norethindrone acetate and ethinyl estradiol, which have been used in swallowable forms since 1968. This new formulation aims to expand access to contraception for those facing swallowing challenges.

“Femlyv is the first FDA approved dissolvable birth control pill, designed for individuals who have trouble swallowing their medication. There are many variables that might cause someone to have difficulty swallowing. This drug provides another treatment option and expands access to this form of contraception for individuals who may have experienced those challenges.”

- Janet Maynard, M.D., M.H.S., director of the Office of Rare Diseases, Pediatrics, Urologic and Reproductive Medicine in the FDA’s Center for Drug Evaluation and Research.

Asia Pacific Contraceptive Drugs and Devices Market Trends

The contraceptive drugs and devices market in Asia Pacific dominated the market with a revenue share of 33.8% in 2024, driven by the increasing need to prevent unwanted pregnancies and manage related health complications. Many women are turning to contraceptives for non-contraceptive health benefits, such as alleviating menstrual pain and treating acne, further driving market expansion. Funding and investment are crucial for market growth due to the rising rates of unintended pregnancies and sexually transmitted diseases (STDs) in the region, which necessitates the development and distribution of effective contraceptive solutions. For instance, in June 2023, Pregna International, a manufacturer of women's contraceptive products, secured 15.22 USD Million (Rs 130 crore) in funding from India Life Sciences Fund.

The contraceptive drugs and devices market in China held a significant share due to the presence of key manufacturing companies and growing awareness about unwanted pregnancies and STDs. Pharmaceutical companies produce large quantities of contraceptive products due to the country’s advanced manufacturing sector and low labor costs. A strong distribution network efficiently distributes these products to customers. The rising population drove the government to increase efforts in educating the public about contraceptive methods. Hence, these factors contributed to positive market growth in the country.

India contraceptive drugs and devices market is experiencing significant growth, driven by increasing awareness of family planning, government initiatives, and a rising demand for effective contraceptive solutions. The country has seen significant advancements in contraceptive options with the launch of new drugs and devices aimed at enhancing family planning services. For instance, in July 2024, the health department initiated a pilot project in four districts, introducing subdermal implants that provide effective contraception for up to three years. These implants are part of efforts to enhance contraceptive options available to women in specific regions. Subdermal implants are now offered at SMS Medical College in Jaipur and RNT Medical College in Udaipur. Additionally, Antara injections, which are administered subcutaneously, have been introduced in the district hospitals of Sawai Madhupur and Jaisalmer.

Europe Contraceptive Drugs and Devices Market Trends

The contraceptive drugs and devices market in Europe is experiencing growth driven by the increasing demand for LARCs, such as IUDs and implants. This demand is influenced by the rising awareness of family planning, government-funded healthcare systems, and growing initiatives to improve reproductive health. For instance, in 2022, the French government provided free contraception for women under 25, free HIV testing without prescriptions, and enhanced abortion access.

The UK contraceptive drugs and devices market is experiencing significant growth, driven by increasing awareness of reproductive health, changing societal norms, and advancements in contraceptive technologies. This market encompasses a variety of products, including hormonal contraceptives, intrauterine devices (IUDs), condoms, and other barrier methods. The NHS is expanding its Pharmacy Contraception Service (PCS), allowing community pharmacies to initiate patients on oral contraception. Pharmacies must opt into this expanded service by February 29, 2024, to continue providing tiered contraception services. This change is part of a broader effort to alleviate pressure on general practitioners and improve access to contraceptive methods.

Contraceptive drugs and devices market in Germany is experiencing significant growth during the forecast period. Better Birth Control has been active in advocating for more diverse contraceptive options for all genders, influencing political platforms and securing funding commitments from the German government. Their efforts are aim to increase accessibility and variety in contraceptive methods available to the public.

Latin America Contraceptive Drugs and Devices Market Trends

The contraceptive drugs and devices market in Latin America is characterized by a growing acceptance of modern contraceptive methods amid cultural shifts and increased education about reproductive health. Initiatives to improve access to family planning services have been implemented, including distributing free contraceptives in public health facilities. Socioeconomic factors and evolving attitudes toward family planning further contribute to increased demand for various methods.

The contraceptive drugs and devices market in Brazil is experiencing significant growth, driven by various factors including the rising incidence of sexually transmitted diseases (STDs) and unplanned pregnancies. The Brazilian government has invested significantly in family planning initiatives, including funding for intrauterine device (IUD) placements and educational programs aimed at raising awareness about contraception. In June 2022, in Brazil, the Ministry of Health invested USD 95 million to carry out 31,600 procedures for the placement of intra-uterine devices (IUDs) in women of childbearing age. This initiative aims to reduce the chances of unplanned pregnancies among young women.

Middle East & Africa Contraceptive Drugs and Devices Market Trends

The contraceptive drugs and devices in the MEA region show diverse trends due to varying cultural, religious, and political factors across different countries. In this region, The Family Planning Policy Atlas 2023, for the Middle East and North Africa highlights the need for improved policies supported by sufficient funding for contraceptives within national health services. It emphasizes the importance of aligning local policies with international guidelines and ensuring public awareness of reproductive rights.

South Africa contraceptive drugs and devices market is experiencing significant growth, driven by increasing awareness of contraceptive options, a high prevalence of unintended pregnancies, and rising government initiatives to promote family planning. In April 2024, the South African health department launched a vending machine in Mthatha, Eastern Cape, which dispenses various sexual and reproductive health products for free. This includes oral contraceptives, emergency contraceptives, condoms, and HIV self-testing kits. The initiative aims to reduce teenage pregnancies and improve access to contraceptives without the stigma often associated with visiting clinics. Users must contact a call center to receive a code for accessing the products, ensuring a degree of privacy.

Key Contraceptive Drugs And Devices Company Insights

Some key emerging companies operating in the market are Abbvie, Inc., Afaxys, Inc., Evofem Biosciences, Inc.,Get Down and Jonny and Jems and Slipp. Companies are focusing on investing in research and development to innovate and produce more effective and accessible contraceptive measures.

Key Contraceptive Drugs And Devices Companies:

The following are the leading companies in the contraceptive drugs & devices market. These companies collectively hold the largest market share and dictate industry trends.

View a comprehensive list of companies in the Contraceptive Drugs and Devices Market

Recent Developments

  • In March 2024, Opill is the first daily oral contraceptive approved for over-the-counter (OTC) sales in the U.S., allowing individuals to purchase it without a prescription. It is a progestin-only pill, making it suitable for a wide range of users. Opill can be found in major retailers and online such as Amazon.

  • In February 2023, Agile Therapeutics, a pharmaceutical and women’s healthcare company, announced a clinical update on Twirla and the status of pipeline evaluation. Twirla is a transdermal system that is a once-weekly combined hormonal contraceptive (CHC) patch. The U.S. Food and Drug Administration (FDA) agreed to address the approval with the help of electronic health records (EHR) and insurance claims from a large database of healthcare systems.

Contraceptive Drugs And Devices Market Report Scope

Report Attribute

Details

Market size value in 2025

USD 32.92 billion

Revenue forecast in 2030

USD 44.04 billion

Growth rate

CAGR of 6.0% from 2025 to 2030

Historical data

2018 - 2024

Forecast period

2025 - 2030

Quantitative units

Revenue in USD million/billion, and CAGR from 2025 to 2030

Report coverage

Revenue forecast, company ranking, competitive landscape, growth factors, and trends

Segments covered

Product, region

Regional scope

North America; Europe; Asia Pacific; Latin America; MEA

Country scope

U.S.; Canada; Mexico; UK; Germany; France; Italy; Spain; Denmark; Sweden; Norway; Japan; China; India; Australia; South Korea; Thailand; Brazil; Argentina; South Africa; Saudi Arabia; UAE; Kuwait

Key companies profiled

AbbVie Inc.; Afaxys, Inc.; Agile Therapeutics; Bayer AG; China Resources (Holdings) Co., Ltd.; Church & Dwight Co., Inc.; Cupid Limited; Helm AG; Johnson & Johnson Services, Inc.; Organon Group; Pfizer Inc.; Veru, Inc.; Viatris Inc.

Customization scope

Free report customization (equivalent up to 8 analysts working days) with purchase. Addition or alteration to country, regional & segment scope.

Pricing and purchase options

Avail customized purchase options to meet your exact research needs. Explore purchase options

Global Contraceptive Drugs And Devices Market Report Segmentation

This report forecasts revenue growth at global, regional, and country levels and provides an analysis of the latest industry trends in each of the sub-segments from 2018 to 2030. For this study, Grand View Research has segmented the global contraceptive drugs and devices market report based on product, and region.

Global Contraceptive Drugs And Devices Market Report Segmentation

  • Product Outlook (Revenue, USD Billion, 2018 - 2030)

    • Contraceptive Drugs

      • Contraceptive Pills

      • Patch

      • Injectable

    • Contraceptive Devices

      • Condoms

        • Male Condoms

        • Female Condoms

      • Subdermal Implants

      • Intrauterine Devices (IUDs)

        • Copper IUDs

        • Hormonal IUDs

      • Vaginal Ring

      • Diaphragm

  • Regional Outlook (Revenue, USD Billion, 2018-2030)

    • North America

      • U.S.

      • Canada

      • Mexico

    • Europe

      • UK

      • Germany

      • France

      • Italy

      • Spain

      • Denmark

      • Sweden

      • Norway

    • Asia Pacific

      • Japan

      • China

      • India

      • Australia

      • South Korea

      • Thailand

    • Latin America

      • Brazil

      • Argentina

    • Middle East and Africa

      • South Africa

      • Saudi Arabia

      • UAE

      • Kuwait

Frequently Asked Questions About This Report

pdf icn

GET A FREE SAMPLE

arrow icn

This FREE sample includes data points, ranging from trend analyses to estimates and forecasts. See for yourself.

gvr icn

NEED A CUSTOM REPORT?

We can customize every report - free of charge - including purchasing stand-alone sections or country-level reports, as well as offer affordable discounts for start-ups & universities. Contact us now

Certified Icon

We are GDPR and CCPA compliant! Your transaction & personal information is safe and secure. For more details, please read our privacy policy.